R logo Ryder System +
Ryder System
+

Ryder System (R) Business News

Track Ryder System in real time with a live news feed covering Ryder System stock news, official press releases, company announcements, and an archive of historical Ryder System news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
2:40 AM | Monday | May 18, 2026 Accesswire

Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

News Thumbnail
2:40 AM | Monday | May 18, 2026 Accesswire

Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

News Thumbnail
10:41 AM | Thursday | May 14, 2026 Zacks Investment Research

Are Investors Undervaluing Ryder System (R) Right Now?

News Thumbnail
9:00 AM | Wednesday | May 13, 2026 Accesswire

Caldwell Announces Relaunch of Canada's Top 40 Under 40(R) Award Program

News Thumbnail
10:00 AM | Tuesday | May 12, 2026 Accesswire

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

News Thumbnail
9:45 AM | Tuesday | May 12, 2026 Accesswire

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

News Thumbnail
8:00 AM | Tuesday | May 12, 2026 Accesswire

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

News Thumbnail
1:50 AM | Tuesday | May 12, 2026 Accesswire

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

News Thumbnail
6:55 AM | Tuesday | May 5, 2026 Business Wire

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

News Thumbnail
8:00 AM | Monday | May 4, 2026 Newsfile Corp

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

News Thumbnail
10:31 AM | Friday | May 1, 2026 Zacks Investment Research

Rosy Used Vehicle Sales, Operational Discipline Aid Ryder's Prospects

News Thumbnail

Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

Accesswire

2:40 AM | Monday | May 18, 2026

news photo
Loading...

LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 in patients with advanced solid tumors, including case studies showing visible tumor uptake of ¹⁷⁷Lu-SN201 in two individuals with different head and neck cancers.

Read full article redirect
2:40 AM | Monday | May 18, 2026

Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

Accesswire

LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 in patients with advanced solid tumors, including case studies showing visible tumor uptake of ¹⁷⁷Lu-SN201 in two individuals with different head and neck cancers.

Read full article arrow
News Thumbnail
2:40 AM | Monday | May 18, 2026

Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

Accesswire

LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 in patients with advanced solid tumors, including case studies showing visible tumor uptake of ¹⁷⁷Lu-SN201 in two individuals with different head and neck cancers.

Read full article arrow
News Thumbnail
10:41 AM | Thursday | May 14, 2026

Are Investors Undervaluing Ryder System (R) Right Now?

Zacks Investment Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Read full article arrow
News Thumbnail
9:00 AM | Wednesday | May 13, 2026

Caldwell Announces Relaunch of Canada's Top 40 Under 40(R) Award Program

Accesswire

TORONTO, ON / ACCESS Newswire / May 13, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the relaunch of Canada's Top 40 Under 40® Award Program, renewing its commitment to recognizing the country's most outstanding young leaders. Caldwell is pleased to be working with Presenting Partner Tourmaline Oil Corp., National Sponsor Deloitte Canada, Travel Sponsor Air Canada, Media Sponsor Financial Post, Event Sponsor Ewing Morris & Co., and Referencing Sponsor Inline Reference Check.

Read full article arrow
News Thumbnail
10:00 AM | Tuesday | May 12, 2026

BioInvent's TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)

Accesswire

40%   objective response rate ( ORR) as single agent in heavily pre - treated patients with advanced Cutaneous T-Cell Lymphoma (CTCL) Durable responses observed, including a complete response lasting over two years and ongoing 50% ORR in combination with KEYTRUDA® (pembrolizumab) Targeting TNFR2 drove robust immune activation, with depletion of regulatory T cells and increased CD8+ T cell infiltration in skin lesions Early immune - related skin reactions - "flares"- correlated with biological activity and immune remodeling Favorable safety profile with mostly mild to moderate treatment - related adverse events LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that new clinical data from its ongoing Phase 2a trial evaluating BI-1808,... Read more

Read full article arrow
News Thumbnail
9:45 AM | Tuesday | May 12, 2026

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

Accesswire

LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. Poster Presentation Title: Targeting resistance to rituximab through FcγRIIB (CD32B) blockade: BI-1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL Presenter: Dr. Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Brazil Session Date/Time: Friday, June 12, 6:45 pm-7:45 pm CEST (12:45 pm-1:45 pm EDT) Location: EHA2026 Congress, Stockholm The presentation will summarize emerging efficacy and safety observations and mechanistic insights from the... Read more

Read full article arrow
News Thumbnail
8:00 AM | Tuesday | May 12, 2026

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Accesswire

~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize abuse and overdose risk, today announced that the Taiwan Intellectual Property Office issued a patent covering Ensysce's MPAR® (Multi-Pill Abuse Resistance) technology. The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof", includes both composition-of-matter and method-of-use claims that strengthen Ensysce's intellectual property estate for its unique overdose protection platform.

Read full article arrow
News Thumbnail
1:50 AM | Tuesday | May 12, 2026

Quarterly Report Q1 2026: Orviglance(R) Approaching Transformative Milestones

Accesswire

MALMÖ, SE / ACCESS Newswire / May 12, 2026 / Ascelia Pharma AB (publ) (STO:ACE) today published its Interim Report Q1 for 2026 (January - March), which is now available on the company's website: Financial Reports - ASCELIA KEY EVENTS IN Q1 2026 Abstract with Orviglance data has been accepted for oral presentation at the annual radiology congress ESGAR 2026 Management changes: Anton Hansson starts as CFO, while Julie Waras Brogren leaves her position as Deputy CEO KEY EVENTS AFTER THE PERIOD Ascelia Pharma completes directed share issue of SEK 20 million before transaction costs FINANCIAL SUMMARY Q1 (Jan-Mar) 2026 Operating result of SEK -17.2M (SEK -20.3M) Earnings per share of SEK -0.13 (SEK -0.23) Cash flow from operations of SEK -15.
9M (SEK -16.9M) Liquid assets and marketable securities of... Read more

Read full article arrow
News Thumbnail
6:55 AM | Tuesday | May 5, 2026

Ryder CEO to Address Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference

Business Wire

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) Chief Executive Officer John Diez will present a company update at the 2026 Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference. Who:  Ryder System, Inc. Chief Executive Officer John Diez What: Bank of America Securities Industrials, Transportation, and Airlines Key Leaders Conference When: Tuesday, May 12, 2026 Time: 11:05 a.m.
Eastern Time Webcast: To access the link to the live webcast, visit: Ryder.

Read full article arrow
News Thumbnail
8:00 AM | Monday | May 4, 2026

Gelum Shares Approved for Trading on the OTCQB(R) Venture Market

Newsfile Corp

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Gelum Resources Ltd. (CSE: GMR) (OTCQB: GMRCF) ("Gelum" or the "Company") reports that the Company's common shares have been re-approved and admitted for trading on the OTCQB Venture Market under the symbol GMRCF commencing May 4, 2026.

Read full article arrow
News Thumbnail
10:31 AM | Friday | May 1, 2026

Rosy Used Vehicle Sales, Operational Discipline Aid Ryder's Prospects

Zacks Investment Research

R's upbeat used-vehicle sales, contractual growth and disciplined operations --- plus dividends and buybacks ---- boost its outlook as freight recovers.

Read full article arrow
News Thumbnail